The United States Food and Drug Administration (USFDA) has conducted an inspection of Panacea Biotec’s material wholly-owned subsidiary, Panacea Biotec Pharma (PBPL) at Baddi, Himachal Pradesh, India between May 30, 2022 and June 08, 2022.
At the end of inspection, PBPL was issued a 'FDA Form 483' with 8 observations which are related to improvements in existing procedures and are addressable. PBPL will respond to the US FDA within the stipulated time period and work closely with US FDA to close the said observations and the closure of Warning Letter issued by the US FDA earlier on September 24, 2020. The company is committed to patient safety and quality and take quality and compliance matters seriously and stand by its commitment to fully comply with the cGMP quality standards.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: